scholarly journals Clinical Pharmacokinetics of Oseltamivir and Its Active Metabolite Oseltamivir Carboxylate after Oral Administration in Horses

2007 ◽  
Vol 69 (3) ◽  
pp. 293-296 ◽  
Author(s):  
Takashi YAMANAKA ◽  
Masayuki YAMADA ◽  
Koji TSUJIMURA ◽  
Takashi KONDO ◽  
Shunichi NAGATA ◽  
...  
Keyword(s):  
Oral Administration ◽  
Active Metabolite ◽  
Oseltamivir Carboxylate ◽  
Clinical Pharmacokinetics

Desmethylmisonidazole (Ro 05–9963): Clinical pharmacokinetics after multiple oral administration

1982 ◽  
Vol 8 (3-4) ◽  
pp. 377-379 ◽  
Author(s):  
M.R.L. Stratford ◽  
A.I. Minchinton ◽  
S. Dische ◽  
F.R. Saunders ◽  
M.I. Anderson
Keyword(s):  
Oral Administration ◽  
Clinical Pharmacokinetics

Influx and Efflux Transporters Contribute to the Increased Dermal Exposure to Active Metabolite of Regorafenib After Repeated Oral Administration in Mice

2019 ◽  
Vol 108 (6) ◽  
pp. 2173-2179 ◽  
Author(s):  
Aya Hasan Al-Shammari ◽  
Yusuke Masuo ◽  
Ken-ichi Fujita ◽  
Yuka Yoshikawa ◽  
Noritaka Nakamichi ◽  
...  
Keyword(s):  
Oral Administration ◽  
Active Metabolite ◽  
Dermal Exposure ◽  
Efflux Transporters

CLINICAL PHARMACOKINETICS OF LORAZEPAM 4, LONG-TERM ORAL ADMINISTRATION

1978 ◽  
Vol 22 (4) ◽  
pp. 324
Author(s):  
D. J. GREENBLATT ◽  
J. A. KNOWLES ◽  
W. H. COMER ◽  
R. I. SHADER ◽  
J. S. HARMATZ ◽  
...  
Keyword(s):  
Oral Administration ◽  
Clinical Pharmacokinetics

scholarly journals Oseltamivir and Oseltamivir Carboxylate Pharmacokinetics in Obese Adults: Dose Modification for Weight Is Not Necessary

2011 ◽  
Vol 55 (12) ◽  
pp. 5640-5645 ◽  
Author(s):  
Manjunath P. Pai ◽  
Thomas P. Lodise
Keyword(s):  
Active Metabolite ◽  
Influenza A ◽  
Systemic Exposure ◽  
Lean Body Weight ◽  
Population Pharmacokinetic ◽  
Class Iii ◽  
Oseltamivir Carboxylate ◽  
Obese Adults ◽  
Time Curve ◽  
Apparent Clearance

ABSTRACTObesity is an independent risk factor for mortality in patients infected with pandemic influenza A virus (H1N1). Given the poor outcomes observed among adult obese patients with H1N1, the dosing of antiviral agents in this population has been questioned, and use of twice the standard oseltamivir dose has been suggested. However, studies evaluating the disposition of oseltamivir and oseltamivir carboxylate (the active metabolite) in the obese population are scant. We evaluated the single-dose and steady-state pharmacokinetics of oseltamivir (75 mg by mouth twice daily) in a cohort of 21 healthy adult volunteers with class III obesity (body mass index [BMI], ≥40 kg/m2). The median (minimum, maximum) age, weight, and BMI were 36 (19, 50) years, 122 (106, 159) kg, and 43.7 (40.0, 54.4) kg/m2, respectively. The population pharmacokinetic exposure profiles of oseltamivir carboxylate (the active metabolite) were comparable between class III obese subjects and nonobese adults (healthy and infected). Similar to previous pharmacokinetic analyses in nonobese subjects, the mean (percent covariance [CV]) area under the concentration-time curve for the dosing interval (AUC0–τ) was 2,621 ng·h/ml (17) for oseltamivir carboxylate. Body size was significantly (P< 0.05) associated with oseltamivir and oseltamivir carboxylate apparent clearance, but the correlation coefficient was poor (R2≤ 0.3). Creatinine clearance estimated by the Cockcroft-Gault method and lean body weight were also significantly (P< 0.05) but poorly (R2= 0.17) correlated with oseltamivir carboxylate apparent clearance. Since the systemic exposure of oseltamivir carboxylate is not reduced in class III obese adults with standard doses, a dose increment of oseltamivir is likely to be unnecessary.

Sign in / Sign up

Export Citation Format

Share Document